grant
Dissecting the Heterogeneous Molecular Mechanisms Underlying Multiple Sclerosis Progression
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Aug 2025Deadline 31 Jul 2030
NIHUS FederalResearch GrantFY2025AccelerationAcuteAnimal ModelAnimal Models and Related StudiesAntibodiesAssayAstrocytesAstrocytusAstrogliaAstroproteinAutomobile DrivingBioassayBiological AssayBiological MarkersBloodBlood ProteinsBlood Reticuloendothelial SystemBlood SerumBody FluidsCNS InjuryCNS Nervous SystemCaringCentral Nervous SystemClinicalCollaborationsComplexData SetDemyelinationsDepartment of DefenseDeteriorationDevelopmentDiseaseDisease ProgressionDisorderDisseminated SclerosisDysfunctionEconomic BurdenEuropeEuropeanEvolutionFunctional disorderFundingFutureGFA-ProteinGFAPGermanyGlial Fibrillary Acid ProteinGlial Fibrillary Acidic ProteinGlial Intermediate Filament ProteinGrantHLA-DR Associated Protein IIIGAADImmuneImmune Cell ActivationImmunesIn VitroInflammationInhibitor of GZMA-Activated DNaseInjuryInternationalMOG glycoproteinMS patientMeasurementMeasuresMolecularMultiple SclerosisMyelinNeuraxisOligodendrocytesOligodendrocytusOligodendrogliaOligodendroglia CellOnset of illnessPathologyPathway interactionsPatternPeripheralPhasePhosphatase 2A Inhibitor I2PP2APhysiopathologyProcessProteinsProteolipidsProteomeProteomicsRelapseResearchRoleSET Translocation Inhibitor-2 of Protein Phosphatase-2ASNAP-25 polypeptideSNAP-25 proteinSamplingSerumSerum MarkersSet proteinSeveritiesStressSynapsesSynapticTechnologyTemplate Activating Factor I BetaVam7 t-SNAREVisitWorkadult youthastrocytic gliabio-markersbiologic markerbiomarkerblood-based biomarkerblood-based markercentral nervous system injurychronic demyelinationcognitive capacitycohortdefined contributiondemyelinatedevelopmentaldisabilitydisease onsetdisorder onsetdrivingglial activationglial cell activationimmune activationindividualized therapeuticinjured CNSinjuriesinsightinsular sclerosismodel of animalmultiple sclerosis patientmyelin oligodendrocyte glycoproteinnew markernovel biomarkernovel markeroligodendrocyte-myelin glycoproteinpathophysiologypathwaypatients with MSpatients with multiple sclerosispeople with Multiple sclerosispersonalized therapeuticpre-clinicalpreclinicalproteomic signatureresponseskill acquisitionskill developmentsnap25 proteinsocial rolesocio-economicsocio-economicallysocioeconomicallysocioeconomicssymptomatologysynapsesynaptosomal-associated protein 25targeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttoolyoung adultyoung adult ageyoung adulthood
Description preview
Abstract
Multiple sclerosis is the most common cause of non-traumatic disability in young adults, with an estimated total
economic burden of $85.4 billion. Irreversible disability accumulation is the most challenging, unmet need
in care for people with multiple sclerosis (pwMS) and drives socioeconomic burden. Disability
accumulates in two…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click